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Abstract
Background: Bloodstream infection (BSI) in children causes significant morbidity and mortality. There are few
studies describing the epidemiology of BSI in South African children.
Methods: A retrospective descriptive cohort study was conducted at a paediatric referral hospital in Cape Town,
South Africa. The National Health Laboratory Service (NHLS) microbiology database was accessed to identify
positive blood culture specimens during the period 2011–2012. Demographic and clinical details, antimicrobial
management and patient outcome information were extracted from medical and laboratory records. Antibiotic
susceptibility results of identified organisms were obtained from the NHLS database.
Results: Of the 693 unique bacterial and fungal BSI episodes identified during the study period, 248 (35.8%) were
community-acquired (CA), 371 (53.5%) hospital-acquired (HA) and 74 (10.7%) healthcare-associated (HCA). The
overall risk was 6.7 BSI episodes per 1000 admissions. Escherichia coli, Staphylococcus aureus and Streptococcus
pneumoniae were the most frequent causes of CA-BSI and Klebsiella pneumoniae, Acinetobacter baumanii and S.
aureus were most commonly isolated in HA-BSI. On multivariable analysis, severe underweight, severe anaemia at
the time of BSI, admission in the ICU at the time of BSI, and requiring ICU admission after BSI was diagnosed were
significantly associated with 14-day mortality.
Conclusion: This study adds to the limited literature describing BSI in children in Africa. Further studies are
required to understand the impact that BSI has on the paediatric population in sub-Saharan Africa.
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Background
Bloodstream infection (BSI) causes significant morbidity
and mortality in children and increase healthcare expend-
iture [1, 2]. In Africa, community-acquired (CA)-BSI was
identified in 5.8% of children presenting to hospital in
Tanzania and up to 19.9% in rural Ghana [3, 4], while
hospital-acquired (HA) BSI was less frequently described.
In a recent study among children hospitalised in a Kenyan
district hospital, the overall risk of acquiring a nosocomial
BSI was 5.9 per 1000 admissions. [5]. South Africa has a
paucity of literature describing BSI in children. In one
study, the risk of CA-BSI and HA-BSI was 16 and 5 per
1000 admissions, respectively [6]. More recent studies
have documented lower pathogen yields and high
contamination rates in blood culture specimens. The
spectrum of pathogens described was similar to elsewhere
in Africa with the exception of lower rates of infection
caused by non-typhoidal Salmonella species [7, 8].
Clinical manifestations of childhood BSI in sub-
Saharan Africa (SSA) are also poorly documented. Fever
may be the only manifestation of childhood invasive in-
fection. In SSA with the added burden of malaria, HIV-
infection, tuberculosis and malnutrition, the treatment
of fever is often syndromic, targeting multiple possible
aetiologies, without necessarily considering BSI as a po-
tential cause [9]. Not all fever is due to malaria, as
shown in a recent Tanzanian study where viruses and
bacteria caused more than 90% of childhood fevers. In
that study only 6.4% of fever episodes were caused by
malaria [10]. In HIV-infected children treated with anti-
retroviral therapy (ART), the risk of BSI is highest in the
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first 3 months after ART initiation with a steady decline
thereafter [11].
Antimicrobial resistance is an important global public
health threat. A systematic review on antimicrobial re-
sistance among gram-negative bacteria in developing
countries including 15 studies from Africa showed that
in children, 50% and 11% of Escherichia coli isolates
were resistant to ampicillin and gentamicin, respectively
and 30% of Klebsiella pneumoniae isolates were resistant
to ceftriaxone [12]. These antimicrobials are used empir-
ically to treat ill children with invasive infection. None
of the studies in this review included children from
South Africa but Dramowski and colleagues recently
showed that more than 75% of K. pneumoniae isolates at
their hospital in Cape Town were extended spectrum
beta-lactamase (ESBL) producing organisms [7].
Despite the growing body of literature there remains
many gaps in our knowledge about the clinical and la-
boratory aspects of BSI in SSA. To address some of
these aspects of BSI in SSA we conducted an observa-
tional study aimed at describing the epidemiology, clin-
ical manifestations and antimicrobial management of
BSI at Red Cross War Memorial Children’s Hospital
(RCWMCH).
Methods
Study design and setting
This retrospective descriptive cohort study was completed
at RCWMCH on children with culture-confirmed BSI, di-
agnosed between 1 January 2011 and 31 December 2012.
RCWMCH is a 273-bed tertiary level paediatric hospital
in Cape Town, Western Cape province, South Africa. The
hospital has emergency, general paediatric, specialised
paediatric, surgical, burns, trauma and intensive care facil-
ities serving as a referral centre for the Western Cape and
surrounding provinces. Dedicated early neonatal care
linked to obstetric services is provided by other hospitals
in Cape Town. However, neonates requiring immediate
surgical care, or medical care after the first 7 days of life
are admitted to RCWMCH.
Study population
Most children hospitalised in RCWMCH originate from
poor, peri-urban communities in the Western Cape.
During the study period there were 43,663 admissions to
the hospital and 16,951 blood culture specimens were
processed from patients with suspected invasive infec-
tion, i.e. 1 blood culture specimen per 2.6 hospital
admissions. The medical microbiology database of the
National Health Laboratory Service (NHLS) was
accessed, and 2084 positive blood culture results of chil-
dren hospitalised at RCWMCH during the study period
were identified. Organisms isolated from these blood
cultures were stratified into pathogens and non-
pathogens. Coagulase-negative staphylococci, Staphylo-
coccus epidermidis, Bacillus spp., Micrococcus spp., viri-
dans streptococci, and coryneform bacteria were
regarded as contaminants and excluded from the ana-
lysis unless they were isolated in two or more independ-
ent blood culture specimens from the same patient
within a 48-h period, in which case they were included
as a pathogen [13]. Within this group of blood culture
results, repeat blood cultures within 14 days of the initial
blood culture and yielding an identical pathogen were
regarded as part of the same potential BSI episode, and
therefore excluded. A recurrent BSI episode was defined
as the isolation of the same or different organism on blood
culture more than 14 days after the initial/previous BSI
episode. To verify each BSI episode (new or recurrent)
identified during this laboratory review, the medical re-
cords of all patients linked to these events were reviewed.
During this process 20 episodes were excluded as they
had been misclassified as BSI episodes. Thus the study
population comprised 548 children who experienced 693
unique bacterial or fungal BSI episodes (Fig. 1).
Data collection
Paper-based medical records of patients with BSI epi-
sodes were reviewed and relevant data was extracted
and manually transferred onto standardised data collec-
tion forms. HIV status was determined using HIV test
results obtained from patient medical and laboratory re-
cords. Microbiological results obtained from the NHLS
database were also entered on the data collection forms.
Microbiological procedures
All microbiology testing was conducted at the Groote
Schuur National Health Laboratory Service (NHLS)
microbiology laboratory. The laboratory uses the BAC-
TEC™ 9240 automated blood culture system (Becton
Dickinson, Sparks, Maryland). For blood culture bottles
flagging positive with mono-morphic Gram-negative ba-
cilli seen on Gram stain, a locally validated method of
direct inoculation into the automated Vitek®2 system
(bioMérieux, Inc., France) was employed, using Vitek®2
ID-GNB and AST-N133 cards for identification and sus-
ceptibility testing respectively. This direct method was
supplemented, where necessary with repeat testing from
bacterial colonies subcultured onto agar plates, using ei-
ther Vitek®2, disk diffusion or gradient diffusion E-test
(bioMérieux, Marcy l’Etoile, France) methods. Standard
biochemical methods and disk diffusion and gradient
diffusion antibiotic susceptibility tests were used to
evaluate Gram-positive organisms, while yeasts were
tested with the Vitek®2’s YST identification and AST-
YS07 cards.
Susceptibility results were interpreted according to
the Clinical Laboratory Standards Institute (CLSI)
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criteria for 2011 and 2012 [14, 15]. Ertapenem mini-
mum inhibitory concentration (MIC) breakpoints for
Gram-negative organisms were revised in 2012, as
were the ciprofloxacin breakpoints for Salmonella spe-
cies. For Pseudomonas species, the breakpoints for
meropenem, imipenem and piperacillin-tazobactam
were revised in 2012.
ESBLs were detected by the Vitek®2 Advanced Expert
system or by the double disk synergy method if using
disk diffusion testing. Despite the changes to reporting
of cephalosporin susceptibility in ESBL-producing or-
ganisms introduced by CLSI in 2010, the laboratory, in
line with the contemporary national practice, continued
to report ESBL- producing Enterobacteriaceae as resist-
ant to all cephalosporins.
Study definitions
BSI was classified as (1) community-acquired (CA) if the
pathogen was isolated within the first 48 h after admis-
sion and did not meet the definition of healthcare-
associated infection, (2) hospital-acquired (HA) if the
pathogen was isolated from a blood culture obtained
more than 48 h after hospitalisation without the patient
having been a resident of a long-term care facility or
hospitalised during the preceding 28 days, or (3) health-
care-associated (HCA) if the pathogen was isolated in a
patient within the first 48 h of being hospitalised from a
long-term care facility, or readmitted within 28 days of
discharge from a hospital or birth facility [5, 13]. BSI
with a clinical focus refers to a laboratory confirmed BSI
event accompanied by one of more clinical sites of
infection such as pneumonia, meningitis, soft tissue
infection or line infection as extracted from the patient’s
medical records.
The HIV status was defined as follows: (1) HIV-in-
fected: a child < 18 months old with a positive HIV
DNA PCR result confirmed by either a quantitative
HIV RNA PCR or repeat HIV DNA PCR test, or a child
≥ 18 months old with 2 positive serological test results
(HIV ELISA or HIV Rapid test) or a positive HIV DNA
PCR result confirmed by either a quantitative HIV
RNA PCR or repeat HIV DNA PCR test, (2) HIV-unin-
fected: a child with a negative HIV serological or HIV
DNA PCR result and (3) Unknown HIV status: a child
with unknown maternal HIV status and who was not
tested for HIV infection.
Moderate and severe underweight for age (UWFA)
were defined as weight-for-age z score (WAZ) between
−2 and −3 standard deviations (SD) below the median
World Health Organisation (WHO) growth reference
standards, and a WAZ < −3 SD respectively [16].
Antimicrobial management at the time of the BSI was
considered to be effective if the organism isolated was
susceptible to the prescribed antimicrobial agent.
Statistical analysis
All data was entered anonymously into an Excel spread-
sheet and analysed using Stata release 12.0 statistical
software package (STATACorp, College Station, Texas).
Continuous variables were expressed as medians (inter-
quartile range, IQR). Frequencies and proportions were
Fig. 1 Selection of BSI episodes for data analysis at Red Cross War
Memorial Children’s Hospital (RCWMCH). *14 post-mortem specimens
and 6 non-blood specimens (peritoneal fluid [3], eye fluid aspirate [1],
pus [1] and lymph node aspirate [1]) inoculated in blood culture bottles
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used to describe categorical variables. Chi-squared and
Kruskal-Wallis tests of association were used to assess
associations between categorical and numerical variables
across the type of BSI for the baseline patient character-
istics and BSI with or without a clinical focus for blood
marker variables. Cox proportional hazards regression
was used to assess factors associated with 14-day mortal-
ity, adjusting for the baseline demographic, clinical and
blood marker variables. P-values < 0.05 were considered
significant.
Results
Classification and risk of bloodstream infection
Overall, 248 (35.8%) CA-, 371 (53.5%) HA- and 74
(10.7%) HCA-BSI episodes were identified. Fewer blood
cultures were processed and fewer BSI episodes occurred
in 2012 compared to 2011. The overall risk of CA-BSI,
HA-BSI and HCA-BSI was 5.7, 8.5 and 1.7 episodes per
1000 admissions, respectively (Table 1).
Baseline characteristics of study participants
Table 2 describes the baseline characteristics of the study
participants at the time of each BSI episode and disag-
gregates the information according to the type of BSI.
The median age at the time of BSI was 11.5 months
(IQR 3.6–50). Furthermore, 40.7% (273/670) of episodes
occurred in children who were moderately or severely
underweight. Of the 524 children (75.6%) whose HIV
status was known at the BSI event, 13.4% (70/524) were
HIV-infected.
Clinical spectrum of bloodstream infections
A clinical site of infection in addition to the bloodstream
was identified in 481/663 (72.5%) of the BSI episodes, of
which 327/481(68.0%) had a single identifiable site of in-
fection. Two or more clinical sites of infection were
identified in the remaining 154 BSI episodes (Table 3).
Pneumonia and gastroenteritis were commonly
diagnosed at the time of the BSI episode. There was no
significant difference in the proportions of BSI episodes
with and without a clinical focus associated with a
temperature ≥ 38° C; 60% (270/450) vs 62.8% (108/172),
RR = 0.99 (95% CI: 0.86–1.14).
Spectrum of organisms
Fifty two different organisms were isolated from the 693
BSI episodes including 11 fungi. Fifty eight percent of the
BSI episodes were caused by gram-negative bacteria, 36%
by gram-positive bacteria and 6% by fungi. Candida albi-
cans (19/42) was the dominant fungal isolate. Cryptococ-
cus neoformans was isolated in one HIV-infected child
with severe immunodeficiency i.e. an absolute CD4 count
of < 20 × 109/L and a CD4 percentage of < 1% (Table 4).
Susceptibility to antimicrobial agents
The majority of Staphylococcus aureus isolates 81/103
(78.6%) were susceptible to cloxacillin. The remaining
22 isolates were methicillin-resistant of which 17 were
HA- BSI, accounting for 17/371 (5%) of all HA-BSI. Of
the 57 S. pneumoniae isolates, 26.3% (15/57) were re-
sistant to penicillin according to meningitis criteria
with MIC > 0.06 μg/ml. Susceptibility testing for ceftri-
axone and vancomycin was conducted in 52 and 21of
the S. pneumoniae isolates, respectively with100% sus-
ceptibility for both antimicrobials. Of the 48 Entero-
coccus isolates, 54.2% (26/48) were susceptible to
ampicillin and all were susceptible to vancomycin.
Table 5 describes antimicrobial susceptibility of the
most commonly isolated Gram-negative organisms. Only
9.9% (9/91) of E.coli isolates were susceptible to ampicil-
lin while 70.3% (64/91) were susceptible to gentamicin.
Thirty four percent (31/92) of all E.coli isolates were
extended-spectrum beta lactamase (ESBL)-producing or-
ganisms of which 10 and 16 were community-acquired
and hospital-acquired respectively, accounting for 4%
(10/248) and 4.3% (16/371) of CA- and HA-BSI, respect-
ively. By contrast, 77.3% (68/88) of K. pneumoniae iso-
lates were ESBL producers which accounted for 16.7%
(62/371) of HA-BSI. No carbapenem-resistant Entero-
bacteriacae (CRE) isolates were identified on blood cul-
ture during the study period. Resistance to both
aminoglycosides and carbapenems was present in 22%
(13/59) of A. baumanii isolates. All A. baumanii isolates
were susceptible to colistin. All non-typhoidal Salmon-
ella ssp. isolates were susceptible to ceftriaxone, with
only a single isolate not susceptible to ampicillin and
ciprofloxacin. Candida albicans and parapsilosis isolates
showed a 100% susceptibility to fluconazole.
Antimicrobial therapy
Information on antimicrobial therapy was available for
92% (638/693) of BSI episodes. The median (IQR) time
Table 1 Classification and risk of bloodstream infection (BSI),
2011–2012
2011 2012 2011–2012
Hospital admissions 22,685 20,978 43,663
Blood cultures processed 9108 7843 16,951
Classification of bloodstream infection (n/N(%))
Community-acquired 151/413 (36.6) 97/280 (34.6) 248/693 (35.8)
Hospital-acquired 214/413 (51.8) 157/280 (56.1) 371/693 (53.5)
Healthcare-associated 48/413 (11.6) 26/280 (9.3) 74/693 (10.7)
Risk of BSI per 1000 hospital admissions
Community-acquired 6.7 4.6 5.7
Hospital-acquired 9.4 7.5 8.5
Healthcare-associated 2.1 1.2 1.7
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Age median (IQR) 9.3 (3.1–39.3) 13.0 (4.0–59.7) 7.1 (1.4–67.0) 11.5 (3.6–50.0)
Age categories, n/N(%)
0–28 days 31 (12.5) 28 (7.5) 16 (21.6) 75 (10.8)
1 - < 2 months 17 (6.9) 17 (4.6) 6 (8.1) 40 (5.8)
2 - < 12 months 88 (35.5) 132 (35.6) 22 (29.7) 242 (34.9)
12 months – < 5 years 67 (27) 106 (28.6) 11 (14.9) 184 (26.5)
> 5 years 45 (18.1) 88 (23.7) 19 (25.7) 152 (21.9)
WAZ median (IQR) −1.2 (−2.5–0.1) −1.8 (−3.4–0.6) −1.9 (−3.3–1.0) −1.6 (−3–0.3)
WAZ categories, n/N (%)
Severe underweight 44/240 (18.3) 103/361 (28.5) 22/69 (31.9) 169/670 (25.2)
Moderate underweight 33/240 (13.8) 60/361 (16.6) 11/69 (15.9) 104/670 (15.5)
Mild-normal 163,240 (67.9) 198/361 (54.8) 36/69 (52.2) 397/670 (59.3)
HIV-infected, n/N (%) 33 (13.3) 33 (8.9) 4 (5.4) 70 (10.1)
HIV-uninfected, n/N (%) 172 (69.3) 232 (62.5) 49 (66.2) 454 (65.5)
HIV not tested, n/N (%) 43 (6.2) 106 (28.6) 21 (28.4) 169 (24.4)
Receiving ART at the time of the BSI in HIV infected child, n/N(%) 11/33 (33.3) 29/33 (87.9) 3/4 (75) 43/70 (61.4)
aN denominator used unless otherwise stated, IQR interquartertile range, BSI bloodstream infection, CA-BSI community-acquired bloodstream infection, HA-BSI
hospital-acquired bloodstream infection, HCA-BSI healthcare-associated bloodstream infection, WAZ weight-for-age z-score, HIV-infected human immunodeficiency
virus infected, ART antiretroviral therapy









n/N (%)) n/N (%) n/N (%) n/N (%)
BSI with no clinical focus 28 (11.6) 131(37.1) 23 (33.8) 182 (27.5)
Hypothermiab 5/28 (17.9) 2/131 (1.5) 0/23 (0) 7/182 (3.8)
Feverc 14/28 (50) 77/131 (58.8) 17/23 (74) 108/182 (59.3)
BSI with a clinical focus 214(88.4) 222(62.9) 45(66.2) 481 (72.5)
Hypothermiab 11/214 (5.1) 4/222 (1.8) 5/45 (11.1) 20/481 (4.2)
Feverc 112/214 (52.3) 136/222 (61.3) 22/45 (48.9) 270/481 (56.1)
Pneumonia 65/214 (30.4) 91/222 (41) 16/45 (35.6) 172/481 (35.8)
Gastroenteritis 67/214 (31.3) 28/222 (12.6) 10/45 (22.2) 105/481 (21.8)
Soft tissue infectiond 18/214 (8.4) 50/222 (22.5) 4/45 (8.9) 72/481 (15)
Meningitis 39/214 (18.2) 1/222 (0.5) 13/45 (28.9) 53/481 (11)
UTI 29/214 (13.6) 20/222 (9) 4/45 (8.9) 53/481 (11)
Line sepsis 4/214 (1.9) 29/222 (13.1) 3/45 (6.7) 36/481 (7.4)
URTI 20/214 (9.3) 8/222 (3.6) 3/45 (6.7) 31/481 (6.4)
Empyema 4/214 (1.9) 5/222 (2.3) – 9/481 (1.9)
Septic arthritis 6/214 (2.8) 3/222 (1.4) – 9/481 (1.9)
Bronchiolitis 4/214 (1.9) – 1/45 (2.2) 5/481 (1)
Pleural effusion – 3/222 (1.4) – 3/481 (0.6)
BSI bloodstream infection, CA-BSI community-acquired bloodstream infection, HA-BSI hospital-acquired bloodstream infection, HCA-BSI healthcare-associated
bloodstream infection, aN = denominator used unless otherwise stated; bBody temperature ≤ 35.5 ° C around the time of BSI; cBody temperature ≥ 38 °C around
the time of BSI; dSoft tissue infection includes skin abscesses, burn wound infections, wound sepsis and infected eczema or scabies, UTI urinary tract infection,
URTI upper respiratory tract infection
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to effective antibiotic therapy for bacterial isolates of CA-,
HA- and HCA- BSI was 0 (0–1) day, 1 (0–2) day and 1
(0–3) day, respectively. The median (IQR) time to effective
antifungal therapy for fungal isolates was 4.5 (4–5) days, 3
(0.5–4) days and 2.5 (2–3) days for CA-, HA- and HCA-
BSI, respectively. Of the 638 episodes, 592 (92.8%)
`received effective antimicrobial therapy based on the sus-
ceptibility profile of the isolate. In the remaining 46 epi-
sodes, 42 were treated with an ineffective antimicrobial,
and 4 fungal BSI episodes did not receive antifungal ther-
apy. Of the 42 bacterial episodes not treated with an ef-
fective antimicrobial, 10 (23.8%) resulted in a fatal
outcome with the median (IQR) time to death of 4 (2–9)
days, and the remaining 32 (76.2%) episodes resolved on
ineffective antibiotic therapy. In 2 of the 4 fungal episodes
that were not treated with antifungal therapy the patients
died before the culture results were known. The
remaining 2 children recovered uneventfully.
Outcomes
85 % (590/693) of BSI episodes were successfully treated
and the children were discharged from hospital after
these episodes. During the study period, 103 (14.9%)
children died during or after a BSI episode prior to hos-
pital discharge. Seventy of these deaths occurred within
14 days as a direct result of the BSI and were included
in the survival analysis as there was a high chance of
correctly identifying relevant risk factors in these
children. The median time (IQR) to death of these 70
children was 3 (1–8) days. Of the 33 deaths that
occurred after 14 days, the median time (IQR) to death
was 46 (23–67) days.
Table 6 describes risk factors associated with 14-day in-
patient mortality in children with BSI. On multivariable
analysis, severe UWFA, severe anaemia at the time of BSI,
admission in the ICU at the time of BSI, and requiring
ICU admission after BSI was diagnosed were significantly
associated with 14-day mortality. HIV-infection was not
associated with increased mortality risk.
Discussion
The current study describes the aetiology and quantifies
the risk of BSI at our hospital. Gram-negative organisms
were the predominant cause of BSI. The risk was lower
for CA-BSI but higher for HA-BSI than rates obtained
in a previous South African study conducted 20 years
previously [6]. The isolation of 5.7% pathogens from
blood culture specimens in the present study is similar
to that from another referral hospital in Cape Town [7].
Possible reasons for the low pathogen yield in our set-
ting may include inadequate volumes of blood inocu-
lated into blood culture specimen bottles, lack of clear
clinical indications for performing blood cultures poten-
tially inflating the number of negative cultures and the
prior use of antimicrobials, particularly ceftriaxone, as
part of the syndromic case management of sick children
at primary health care facilities [5, 9, 17]. The contaminant
prevalence of 6.6% from 16,951 blood cultures is more
than double the internationally acceptable contamination
rate of 2–3%, suggesting that urgent attention is needed to
improve aseptic measures when obtaining specimens for
blood culture [18, 19]. A previous analysis of blood culture
results over a 5-year period (2008–2012) from the same
institution highlighted problems of high contamination
rates particularly in the less than one-year age group and
low pathogen yield, and also documented the predomin-
ance of gram-negative pathogens. [8].
S. aureus, E.coli, K. pneumoniae and A. baumanii
predominated in our study. This spectrum of organisms
is similar to that documented in other African studies
[5–7]. Non-typhoidal Salmonella is a much more fre-
quent cause of BSI in African countries to the north of
South Africa, especially those in malaria-endemic areas,










(N = 248) (N = 371) (N = 74) (N = 693)
Gram-negative bacteria 117 (47.2) 240 (64.7) 43 (58.1) 400 (57.7)
Escherichia coli 49 (19.8) 33 (8.9) 10 (13.5) 92 (13.3)
Klebsiella pneumoniae 5 (2) 78 (21) 9 (12.2) 92 (13.3)
Acinetobacter baumanii 4 (1.6) 54 (14.6) 1 (1.4) 59 (8.5)
Pseudomonas aeruginosa 3 (1.2) 19 (5.1) 4 (5.4) 26 (3.8)
Non-typhoidal Salmonella 11 (4.4) 6 (1.6) 3 (4.1) 20 (2.9)
Enterobacter cloacae 3 (1.2) 12 (3.2) 3 (4.1) 18 (2.6)
Serratia marcescens 0 (0) 17 (4.6) 1 (1.4) 18 (2.6)
Neisseria meningitidis 12 (4.8) 0 (0) 1 (1.4) 13 (1.9)
Haemophilus influenza B 6 (2.4) 1 (0.3) 2 (2.7) 9 (1.3)
Salmonella typhi 4 (1.6) 0 (0) 0 (0) 4 (0.6)
Other 20 (8.1) 20 (5.4) 9 (12.2) 49 (7.1)
Gram-positive bacteria 124 (50) 97 (26.1) 28 (37.8) 249 (35.9)
Staphylococcus aureus 55 (22.2) 37 (10) 11 (14.9) 103 (14.9)
Streptococcus
pneumoniae
45 (18.1) 6 (1.6) 6 (8.1) 57 (8.2)
Enterococcus faecalis 4 (1.6) 23 (6.2) 5 (6.8) 32 (4.6)
Streptococcus group B 13 (5.2) 0 (0) 4 (5.4) 17 (2.5)
Enterococcus faecium 2 (0.8) 14 (3.8) 0 (0) 16 (2.3)
Other 5 (2) 17 (4.6) 2 (2.7) 24 (3.5)
Mycobacterium tuberculosis 1 (0.4) 1 (0.3) 0 (0) 2 (0.3)
Fungi 6 (2.4) 33 (8.9) 3 (4.1) 42 (6.1)
Candida albicans 1 (0.4) 16 (4.3) 2 (2.7) 19 (2.7)
Candida parapsilosis 1 (0.4) 9 (2.4) 1 (1.4) 11 (1.6)
Other Candida species 4 (1.6) 8 (2.2) 0 (0) 12 (1.7)
N = denominator used unless otherwise stated
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but has been reported as an important cause of BSI in
an early South African study [20].
At the time of BSI, 27.5% of the episodes were not asso-
ciated with a clinical focus of infection and 65.1% had
fever (≥ 38 °C) or hypothermia (< 35.5 °C). A study done
in Guinea-Bissau showed that the sensitivity of fever for
detecting BSI was low at 54% with a positive predictive
value (PPV) of 12% [21]. However, a Tanzanian study
showed that temperature ≥ 38.5 °C was a strong predictor
of BSI (odds ratio (OR) 7, 95% CI: 2.2–14.8, P = 0.0001) al-
though the number of patients enrolled in that study was
small [22]. Furthermore, a Malawian study of 225 hospita-
lised children found that the presence of at least one of
five clinical features (oral thrush, malnutrition, chronic
cough, lethargy on history and lethargy on examination)
predicted BSI with a sensitivity of 69% [23].
Severe underweight was present in 25.2% of children
in our study and was a significant predictor of 14-day
mortality. These findings are in agreement with previous
African studies showing that severe malnutrition signifi-
cantly increases the risk of BSI, and that nutritional sta-
tus is a significant determinant of survival in children
with BSI [5, 24]. Although HIV infection was known to be
present in 13.4% of the study cohort it did not influence
14-day mortality. Approximately 60% of the HIV-infected
group was on ART at the time of BSI. This may partly ex-
plain why HIV infection did not influence mortality.
Our results show that ESBL-producing K. pneumoniae
and E. coli have become important causes of CA- and
HA-BSI. Of particular concern was that 30% of E.coli
isolates in the CA-BSI group were ESBL-producing or-
ganisms. A recent study from another Cape Town
hospital documented lower prevalence of CA-BSI caused
by ESBL-producing E.coli (11.2%) and HA-BSI caused by
ESBL-producing K.pneumoniae (78.3%) [7]. Although
carbapenem-resistant Enterobacteriaceae infection was
not observed during the study period, carbapenem over-
utilisation as observed in the present study (data not
shown) may with time lead to the emergence of carba-
penem resistant BSI isolates.
Study strengths and limitations
The study describes the spectrum of organisms causing
BSI in children. The results obtained highlight the grow-
ing concern of antibiotic resistance developing particu-
larly in CA–BSI. One limitation was the lack of
susceptibility data for piperacillin-tazobactam due to
technical limitations at the time of the study. With on-
going surveillance of organisms causing BSI and their
susceptibility patterns, empiric antimicrobial choices
may need to be altered in the future. Subsequent to the
study period, updated definitions of reporting laboratory
confirmed BSI were release by the CDC [25]. These defi-
nitions were not utilised in the current study and as a
result, few of the HA-BSI episodes may have been mis-
classified. Organisms implicated in mucosal barrier in-
jury BSI were also not stratified.
Due to the retrospective study design, there are limita-
tions in the completeness and availability of clinical and
laboratory data. The true burden of community-
acquired BSI may have been underestimated. Before sick
children are referred from primary and secondary health
facilities to our hospital, they are often administered
broad-spectrum antibiotics. This practice is consistent
Table 5 Rates of antimicrobial susceptibility for the common gram-negative organisms identified
Acinetobacter






aeruginosa (N = 26)
Non-typhoidal





















Ampicillin – – 91 9 (9.9) 92 – – – 20 19 (95)
Co-amoxyclava – – 89 43 (48.3) 91 27 (29.7) – – 1 1 (100)
Ceftriaxone – – 90 59 (65.6) 88 20 (22.7) – – 20 20 (100)
Ceftazidime 59 24 (40.7) 91 60 (65.9) 91 20 (22) 26 23 (88.5) 1 1 (100)
Ciprofloxacin 59 45 (76.3) 87 70 (80.5) 85 52 (61.2) 26 15 (57.7) 19 18 (94.7)
Piperacillin-
tazobactam
58 10 (17.2) 6$ 5 (83.3) 49$ 34 (69.4) 7$ 1 (14.3) 1$ 1 (100)
Gentamicin 59 27 (45.8) 91 64 (70.3) 89 25 (28.1) 25 15 (60) – –
Amikacin 58 26 (44.8) 92 77 (83.7) 91 70 (76.9) 26 16 (61.5) – –
Meropenem 56 26 (46.4) 92 92 (100) 92 92 (100) 26 22 (84.6) 20 20 (100)
Imipenem 49 27 (55.1) 90 90 (100) 90 90 (100) 26 21 (80.8) 20 20 (100)
Ertapenem 92 92 (100) 91 91 (100) – – 20 20 (100)
Colistin 59 59 (100) 90 90 (100) 89 89 (100) 26 23 (88.5) – –
aCo-amoxyclav = Amoxycillin-clavulanic acid co-formulation $ due to technical limitations with the Vitek®2 AST card piperacillin-tazobactam was infrequently
reported in 2011–2012; No number
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with the World Health Organization Integrated Manage-
ment of Childhood Illness guidelines that have been im-
plemented in South Africa, and frequently results in no
growth on blood culture [9]. Even though the study co-
hort included neonates, the results obtained would not
be an accurate reflection of the burden of BSI in this
special group of infants. We were only able to explore a
limited number of potential risk factors of BSI mortality.
Further studies with larger sample sizes are required to
provide a more in depth understanding of this aspect of
BSI. Furthermore, it was not possible to explore risk fac-
tors associated with the acquisition of a BSI due to the
lack of a suitable control group of children without BSI.
Conclusion
Our study provides insights about the risk, aetiology,
clinical manifestations, antimicrobial therapy and out-
comes of BSI in a sub-Saharan African setting
characterized by high HIV prevalence. Further studies
are required to gain a comprehensive understanding of
the impact of BSI on the childhood population in SSA.
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Table 6 Risk factors associated with 14-day inpatient mortality in children with BSI
Factor Univariate HR (95% CI) P value Adjusted HR (95%CI) P value
Age N = 693
0–28 days 0.9 (0.4–2) 0.834 1
1 - < 2 months 2.2 (1.1–4.6) 0.035 1
2 - < 12 months 1.2 (0.8–2) 0.376 1
12 months – 5 years 0.7 (0.4–1.2) 0.219 1
> 5 years 1 1
Nutritional status N = 693
Severe underweight for age 2.4 (1.5–3.9) 0.0001 2.0 (1.2–3.3) 0.007
Moderate underweight for age 1.1 (0.6–2) 0.851 1
Mild-normal weight for age 1 1
Weight not recorded 2.4 (1–5.9) 0.060 4.9 (1.2–20.8) 0.029
Haemoglobin N = 693
Severe anaemia (< 7 g/dL) 3.3 (1.7–6.4) 0.001 2.7 (1.3–5.6) 0.006
Mild anaemia (7–11 g/dL) 1 (0.6–1.7) 0.909 1
No anaemia (≥ 11 g/dL) 1 1
Result not available 3.7 (1.2–11.9) 0.025 4.2 (1.3–13.7) 0.018
ICU management N = 693
ICU resident at time of BSI 1.5 (0.89–2.7) 0.124 6.5 (3.7–11.6) 0.0001
BSI requiring ICU management 5.2 (3.3–8.4) 0.0001 3.5 (1.8–6.7) 0.0001
BSI not requiring ICU management 1 1
Type of BSI N = 693
CA 1 1
HA 1.2 (0.8–2) 0.377 1
HCA 0.9 (0.4–1.9) 0.806 1
HIV infection N = 693
Yes 1.5 (0.8–2.9) 0.221 1
No 1 1
Unknown status 0.8 (0.5–1.5) 0.523 1
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